Tirzepatide in Thao Dien: Long-Term Weight Maintenance, Treatment Discontinuation, and Evidence Gaps
Featured Answer: What Happens When Tirzepatide Is Discontinued?
Clinical evidence indicates that many adults regain a substantial portion of lost weight after stopping tirzepatide. In SURMOUNT-4, participants who switched from tirzepatide to placebo after an initial 36-week treatment period regained an average of 14.0% of their week-36 body weight over the following 52 weeks, while participants who continued tirzepatide lost an additional 5.5%.
This does not mean every individual will regain the same amount or that weight regain is inevitable at an identical rate. It does show that the biological and behavioral factors contributing to obesity often persist after medication is withdrawn. Important evidence gaps remain regarding optimal maintenance strategies, planned discontinuation, lower-dose maintenance, long-term outcomes after stopping, and which individuals can sustain weight reduction without continued pharmacotherapy.
Research Snapshot
- Primary compound: Tirzepatide, a dual GIP and GLP-1 receptor agonist.
- Central question: How durable are weight and metabolic improvements after treatment ends?
- Key withdrawal trial: SURMOUNT-4, a randomized-withdrawal study in adults with overweight or obesity without diabetes.
- Initial treatment phase: 36 weeks of open-label tirzepatide, during which participants lost an average of 20.9% of body weight.
- Withdrawal phase: 52 weeks of continued tirzepatide or placebo after randomization.
- Longer-term evidence: SURMOUNT-1 provides 176-week data in participants with obesity and prediabetes, followed by a 17-week off-treatment period.
- Main limitation: Evidence on weight maintenance while treatment continues is stronger than evidence on the best way to stop, taper, or transition from treatment.
Key Takeaways
- Tirzepatide can produce substantial weight reduction, but stopping treatment can lead to clinically meaningful weight regain.
- SURMOUNT-4 directly compared continued treatment with withdrawal to placebo and demonstrated different weight trajectories over the following year.
- Weight regain after discontinuation can coincide with deterioration in waist circumference, blood pressure, glycemic measures, and lipid-related markers.
- Obesity is a chronic, relapsing disease for many people; reaching a target weight does not necessarily mean the underlying drivers have disappeared.
- The three-year SURMOUNT-1 results in participants with obesity and prediabetes support sustained benefit during treatment, but they do not establish what happens over several years after discontinuation.
- There is no universally validated tirzepatide discontinuation protocol proven to prevent weight regain in all patients.
- Future research needs to compare maintenance strategies, study treatment interruptions, include diverse populations, and measure patient-important long-term outcomes.
1. Why Weight Maintenance Matters as Much as Weight Loss
Weight-loss research often emphasizes the percentage of body weight lost at a particular trial endpoint. That measure is important, but it answers only one question: how much did body weight change during the period studied?
Long-term management raises different questions. Can the reduction be maintained? What happens to appetite, energy intake, and cardiometabolic risk if treatment stops? Does the intervention need to continue to preserve its benefits? Can alternative strategies sustain the outcome after medication withdrawal?
These questions matter because obesity is influenced by interacting biological, behavioral, environmental, and social factors. After substantial weight loss, appetite-related signals and energy expenditure can change in ways that make maintaining the lower weight difficult. The end of a treatment course does not necessarily remove those pressures.
Tirzepatide is particularly relevant to this discussion because clinical trials have measured both continued treatment and withdrawal. The results provide evidence that weight maintenance is not simply the final stage of a successful short-term intervention. It is a separate clinical and research challenge.
For additional educational context on metabolic signaling and peptide research, visit the Vietnam Peptides Knowledge Hub.
2. How Tirzepatide Produces Weight Reduction
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These incretin pathways influence glucose regulation, appetite-related signaling, and other aspects of nutrient handling.
In clinical studies, tirzepatide has reduced body weight and improved glycemic measures in the populations studied. Its effects on appetite and food intake contribute to weight reduction, while its actions on glucose regulation are especially relevant in type 2 diabetes.
However, the clinical response during treatment should not be confused with a permanent change in the mechanisms regulating body weight. A medicine can alter appetite-related signals while it is being used without permanently removing the biological pressures that contributed to weight gain.
This distinction helps explain why weight maintenance after discontinuation requires separate investigation. Demonstrating substantial weight loss during treatment does not establish that the same outcome will persist after the pharmacological effect is removed.
3. What SURMOUNT-4 Was Designed to Test
SURMOUNT-4 was a phase 3 randomized-withdrawal trial designed to evaluate whether continuing tirzepatide helped maintain weight reduction after an initial treatment period.
The trial enrolled adults with a BMI of at least 30, or at least 27 with a weight-related complication, who did not have diabetes. Participants first received open-label tirzepatide for 36 weeks, with treatment escalated to a maximum tolerated dose of 10 mg or 15 mg once weekly.
At week 36, 670 participants who had entered the randomized phase were assigned either to continue tirzepatide or to switch to placebo for another 52 weeks. Lifestyle counseling was provided during the study.
The design is important because the randomized comparison began after participants had already experienced substantial weight reduction. It therefore addressed maintenance following an initial response rather than comparing treatment initiation with placebo from the outset.
However, this design also limits generalization. Participants entering the randomized phase had completed the initial treatment period and were eligible for randomization. The results may not represent every person starting tirzepatide, including those who stop early because of tolerability, access, cost, or other reasons.
Primary publication: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial, published in JAMA in 2024.
4. SURMOUNT-4 Results: Continued Treatment Versus Withdrawal
During the 36-week open-label phase, participants experienced an average weight reduction of 20.9%. The randomized phase then showed a marked difference between continued treatment and withdrawal.
| Measure | Continued tirzepatide | Switched to placebo |
|---|---|---|
| Initial weight change by week 36 | Average reduction of 20.9% before randomization | Average reduction of 20.9% before randomization |
| Weight change from week 36 to week 88 | −5.5% | +14.0% |
| At least 80% of initial weight loss maintained at week 88 | 89.5% | 16.6% |
| Overall weight change from baseline to week 88 | −25.3% | −9.9% |
The 14.0% increase in the placebo group was calculated relative to body weight at week 36, when participants were randomized. It should not be confused with a 14-percentage-point increase from the original baseline weight or with the percentage of initial weight loss regained.
The trial demonstrated that, on average, continued treatment maintained and extended weight reduction, while withdrawal led to substantial regain. It did not show that every participant regained the same amount or that continued medication is the only possible maintenance strategy.
The randomized evidence is nevertheless strong on one specific question: in this study population, after an initial response to tirzepatide, continuing treatment produced a more favorable weight trajectory over the next 52 weeks than switching to placebo.
5. Why Weight Regain Can Occur After Discontinuation
Weight regain after stopping an effective weight-management medicine should not automatically be interpreted as a failure of motivation. Body weight is regulated by multiple interacting systems, and the physiological environment after weight loss can differ from the environment before treatment.
Appetite-related signals may return
Tirzepatide affects pathways involved in appetite and energy intake while treatment is active. After discontinuation, the drug’s pharmacological effects diminish. Hunger, food-related motivation, and energy intake may change as the body responds to the absence of treatment.
These responses vary between individuals. Trial-level averages cannot predict exactly how appetite or food intake will change in a particular person.
Energy expenditure adapts to weight loss
A smaller body generally requires less energy to maintain than a larger body. In addition, weight loss can be accompanied by adaptive changes in energy expenditure. These factors can make continued weight reduction harder and weight regain easier than a simple calorie calculation might suggest.
Not all weight regain is explained by one mechanism. Appetite, activity, environmental conditions, sleep, medications, stress, and the underlying biology of obesity can all contribute.
The underlying condition may persist
If the factors contributing to obesity remain present after treatment ends, weight management may become more difficult again. This is consistent with the broader clinical understanding of obesity as a chronic disease that can relapse after successful treatment.
The implication is not that medication must continue indefinitely for every person. Rather, decisions about maintenance need to account for the possibility that the treatment’s benefits may diminish after its pharmacological effects are removed.
6. Does Weight Regain Also Affect Cardiometabolic Health?
Body weight is only one dimension of metabolic health. Waist circumference, blood pressure, glycemic control, and lipid-related markers can also change during weight reduction and after treatment withdrawal.
A 2025 post hoc analysis of SURMOUNT-4 examined cardiometabolic changes according to the amount of weight participants regained after stopping tirzepatide. It included participants who had lost at least 10% of body weight during the initial treatment period and were then randomized to placebo.
Greater weight regain was associated with greater reversal of several improvements observed during initial treatment. For example, the increase in waist circumference from week 36 to week 88 ranged from 0.8 cm in the group regaining less than 25% of the weight lost to 14.7 cm in the group regaining at least 75% of the weight lost.
Across the same categories, systolic blood pressure increased by approximately 6.8 to 10.4 mm Hg. HbA1c increased by approximately 0.14 to 0.35 percentage points, with larger increases in the groups that regained more weight.
These findings suggest that the extent of weight regain can be associated with the degree to which selected cardiometabolic improvements are reversed. Because this was a post hoc analysis, it should be interpreted as evidence of an association within the trial data, not proof that weight regain alone caused every observed change.
It also does not establish what happens to long-term rates of heart attack, stroke, kidney failure, or mortality after tirzepatide is discontinued. Those questions require appropriately designed studies with relevant clinical outcomes.
Read the analysis: Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
7. What Three-Year SURMOUNT-1 Data Tell Us—and What They Do Not
A longer-term analysis of SURMOUNT-1, published in the New England Journal of Medicine in 2025, evaluated participants with obesity and prediabetes who received tirzepatide or placebo for 176 weeks, followed by a 17-week off-treatment period.
At week 176, mean body-weight changes were:
- Tirzepatide 5 mg: −12.3%.
- Tirzepatide 10 mg: −18.7%.
- Tirzepatide 15 mg: −19.7%.
- Placebo: −1.3%.
During the 176-week treatment period, type 2 diabetes was diagnosed in 1.3% of participants in the tirzepatide groups compared with 13.3% in the placebo group. After the additional 17-week off-treatment period, the corresponding proportions were 2.4% and 13.7%.
These results provide important evidence that substantial weight reduction and a lower observed incidence of type 2 diabetes can be sustained during prolonged treatment in the studied population. They also show that the lower observed diabetes incidence did not disappear immediately during the short off-treatment follow-up.
However, a 17-week off-treatment period is not equivalent to several years of follow-up after stopping. The study does not establish the long-term weight trajectory after discontinuation, the durability of diabetes-risk reduction over many years, or an optimal strategy for ending treatment.
It is also important not to treat the SURMOUNT-1 prediabetes findings as directly interchangeable with SURMOUNT-4. The trials had different designs and populations, and SURMOUNT-4 specifically randomized participants to continued treatment or withdrawal after an initial response.
Primary publication: Tirzepatide for Obesity Treatment and Diabetes Prevention.
8. What Systematic Reviews Say About Weight Regain After Weight-Management Medication
Evidence from medication classes beyond tirzepatide helps place the withdrawal findings in a broader context. A 2026 systematic review and meta-analysis published in The BMJ examined weight regain after stopping weight-management medications.
The review estimated that, across weight-management medicines, participants regained an average of approximately 4.8 kg during the first year after discontinuation. Estimates for incretin-based medicines and newer, more effective incretin therapies were higher, at approximately 6.0 kg and 9.9 kg, respectively.
The review also projected that average body weight could return to baseline around 1.5 to 1.7 years after stopping treatment, depending on the medication category. These longer-term estimates were model-based projections rather than direct observations throughout that entire period. For newer incretin medicines, follow-up data beyond 52 weeks after stopping were limited.
These results support the general observation that weight regain after medication withdrawal is common. They should not be treated as a precise forecast for an individual taking tirzepatide, because the analysis included different medications, study designs, populations, and follow-up periods.
A separate 2026 systematic review and nonlinear meta-regression focusing on GLP-1 receptor agonists estimated that approximately 60% of weight lost during treatment was regained one year after cessation. Its model projected a plateau below the full amount of weight lost, but the estimate beyond observed follow-up depended on extrapolation. It should not be presented as a proven long-term trajectory for tirzepatide specifically.
These reviews are useful for identifying broad patterns, but direct tirzepatide trials remain essential when making compound-specific claims.
9. Why Discontinuation Evidence Still Has Important Gaps
The available evidence establishes that weight regain can occur after stopping tirzepatide. It is less complete on how to prevent regain safely and effectively once treatment ends.
Gap 1: The optimal discontinuation strategy is unknown
SURMOUNT-4 tested a switch to placebo after the initial treatment phase. It was not designed to compare multiple planned dose-reduction schedules or establish whether tapering is superior to stopping at once for long-term weight maintenance.
Consequently, the trial does not establish a universally effective discontinuation protocol. A strategy that works in one clinical context may not produce the same outcome in another.
Gap 2: Evidence for lower-dose maintenance is limited
Maintaining weight loss with a lower medication exposure is an important research question. However, evidence from a withdrawal trial comparing continued treatment with placebo cannot determine the optimal maintenance dose for every patient.
Future randomized trials could compare different maintenance strategies, including continued treatment at different approved doses, with clearly defined efficacy, safety, and quality-of-life outcomes.
Gap 3: Long-term post-discontinuation follow-up is limited
Many trials provide detailed information during treatment and shorter follow-up after withdrawal. Longer follow-up is needed to understand whether weight regain continues, slows, or stabilizes over several years and how that trajectory relates to cardiometabolic outcomes.
Gap 4: Individual predictors of successful maintenance are not fully established
People differ in baseline health, magnitude of weight loss, treatment duration, appetite response, physical activity, access to support, and reasons for stopping. More research is needed to determine which factors reliably predict durable weight maintenance after discontinuation.
Subgroup associations do not necessarily establish a clinically useful prediction tool. Predictors need to be validated in independent populations before they can guide treatment decisions confidently.
Gap 5: The effect of stopping on clinical events remains uncertain
Changes in weight, HbA1c, blood pressure, or lipids can indicate a shift in cardiometabolic risk. But a short-term change in these markers does not quantify the long-term effect of discontinuation on heart attacks, strokes, kidney outcomes, or mortality.
Dedicated studies with adequate follow-up and clinically meaningful endpoints are needed to answer those questions.
Gap 6: Real-world discontinuation differs from trial withdrawal
Clinical trials provide structured follow-up and defined treatment conditions. In routine care, discontinuation may occur because of cost, supply interruptions, adverse effects, changing insurance coverage, personal preference, pregnancy planning, or other medical circumstances.
Real-world studies can help identify the consequences of these different reasons for stopping, although observational studies must account for confounding and differences between people who discontinue and those who continue treatment.
10. Is Obesity Medication Intended to Be Long-Term Treatment?
For many people, obesity behaves as a chronic condition with a risk of recurrence after treatment ends. This has led clinical guidance to emphasize long-term management rather than assuming that medication should always stop once a target weight is reached.
The American Diabetes Association’s 2025 standards on pharmacological treatment of obesity recommend continuing obesity medications after treatment goals are achieved when appropriate, noting that discontinuation often results in weight recurrence and worsening or re-emergence of cardiometabolic risk factors or obesity-related complications.
The guidance also emphasizes individualized maintenance treatment. A maintenance approach should balance efficacy, health benefits, and tolerability rather than assume that the highest approved dose is necessary for every person in every circumstance.
This is a general clinical principle, not an instruction that every patient must remain on tirzepatide indefinitely. Decisions depend on the person’s medical indication, treatment response, safety, preferences, access, and applicable prescribing information.
For the relevant clinical recommendations, see the Standards of Care in Overweight and Obesity from the American Diabetes Association.
11. What Can Be Done About Maintenance? Separating Evidence From Assumptions
It is tempting to translate withdrawal findings into a single universal maintenance plan. The evidence does not yet justify that approach. Instead, research and clinical discussions should distinguish strategies supported by general principles from strategies that have been proven in dedicated tirzepatide discontinuation trials.
| Strategy or question | What current evidence supports | What remains uncertain |
|---|---|---|
| Continued treatment when clinically appropriate | SURMOUNT-4 showed better average weight maintenance with continued tirzepatide than with withdrawal. | The best long-term treatment approach for every individual. |
| Nutrition and physical activity support | Lifestyle support is an important part of comprehensive weight management and was incorporated into clinical trial settings. | Which specific program reliably prevents regain after tirzepatide withdrawal, and for whom. |
| Dose reduction before stopping | A reasonable research question for individualized maintenance studies. | Whether a particular tapering schedule reduces weight regain or improves outcomes compared with other approaches. |
| Switching to another weight-management treatment | Treatment selection can be individualized according to clinical context and approved options. | The best switching sequence and comparative long-term outcomes after tirzepatide discontinuation. |
| Monitoring after stopping | Weight and relevant health measures can help identify changes after treatment ends. | The optimal monitoring schedule and the best validated thresholds for initiating a new strategy. |
The key point is that evidence for continued treatment is not the same as evidence for a particular discontinuation strategy. A well-designed study is needed to determine whether planned tapering, lower-dose maintenance, structured behavioral support, or switching to another therapy changes long-term outcomes.
12. Safety and the Reasons People Stop Treatment
Discontinuation is not always a planned decision after reaching a weight target. Some people stop because of adverse effects, access barriers, cost, supply interruptions, or other clinical circumstances. These reasons matter because they can influence both the likelihood of stopping and the subsequent health trajectory.
Gastrointestinal tolerability
Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are among the common adverse effects reported with tirzepatide. These effects can affect treatment persistence. A discontinuation study that includes only people who tolerate the initial treatment period may not fully represent people who stop earlier because of adverse effects.
Medical review when stopping is being considered
Whether treatment should continue, be interrupted, or be discontinued depends on the indication, clinical response, adverse effects, other medicines, and the applicable prescribing information. People using tirzepatide for type 2 diabetes may also need to consider how stopping affects glucose management and their wider treatment plan.
Regulatory and product context
Approved indications and product information vary by jurisdiction. Tirzepatide should not be treated as interchangeable across approved prescription products and unapproved or research-grade products. Evidence from controlled trials applies to the studied intervention and population, not automatically to every product marketed under a similar name.
For official US product information, see the Mounjaro prescribing information. The applicable local label should be consulted for country-specific indications and warnings.
13. Evidence Gaps Researchers Should Prioritize
The next generation of weight-maintenance studies should address the limitations that current trials cannot fully resolve.
- Longer follow-up after withdrawal: Track weight, glycemic measures, blood pressure, lipids, quality of life, and clinical outcomes over several years where feasible.
- Randomized maintenance comparisons: Compare continued treatment, different maintenance approaches, and planned discontinuation strategies.
- Broader study populations: Include people with different baseline health profiles, age groups, socioeconomic circumstances, and reasons for treatment initiation or discontinuation.
- Real-world access and persistence: Study the effects of cost, supply, insurance coverage, tolerability, and treatment interruptions.
- Patient-centered outcomes: Assess not only body weight but also physical function, mental well-being, treatment burden, and quality of life.
- Clinical outcomes: Determine whether the weight and metabolic changes observed after withdrawal translate into differences in diabetes incidence, cardiovascular events, kidney outcomes, or mortality.
- Independent replication: Expand the evidence base through independent research and transparent reporting of funding, conflicts of interest, missing data, and limitations.
These research priorities would help clarify whether the best long-term approach is continued pharmacotherapy, an individualized maintenance strategy, a transition to another treatment, or a combination of approaches depending on the clinical context.
14. Frequently Asked Questions
Many do. In SURMOUNT-4, participants switched to placebo after 36 weeks of tirzepatide regained an average of 14.0% of their week-36 body weight over the next 52 weeks. Individual outcomes vary, and the study does not predict exactly what will happen to every person.
Participants entering the randomized phase had lost an average of 20.9% of their body weight during the initial 36-week open-label tirzepatide period.
Yes. During the 52-week randomized phase, participants who continued tirzepatide lost an additional 5.5% of their week-36 body weight on average, while the group switched to placebo regained 14.0%.
No. Trial averages do not describe every individual’s trajectory. Some participants regained less than others, and some maintained a substantial portion of their initial loss. Current evidence does not provide a precise prediction for every person.
A post hoc SURMOUNT-4 analysis found that greater weight regain was associated with greater reversal of several improvements in waist circumference, blood pressure, HbA1c, and other markers. These associations do not by themselves prove what will happen to long-term clinical events.
No. The 176-week SURMOUNT-1 treatment period demonstrated sustained weight reduction during treatment in participants with obesity and prediabetes. The additional off-treatment period lasted 17 weeks, which is not enough to establish a multi-year post-discontinuation trajectory.
There is no universally validated discontinuation protocol proven to prevent regain for everyone. SURMOUNT-4 compared continued treatment with switching to placebo; it did not establish the best tapering schedule, lower-dose maintenance strategy, or switching approach.
Not necessarily for every individual. Obesity may require long-term management, and evidence supports continued treatment for maintaining weight reduction in studied populations. Decisions about duration must be individualized according to indication, benefits, tolerability, safety, preferences, and clinical guidance.
Major gaps include long-term follow-up after stopping, randomized comparisons of maintenance strategies, predictors of successful maintenance, the impact of real-world access barriers, and clinical outcomes such as cardiovascular events and mortality after discontinuation.
Weight maintenance is a distinct treatment challenge. Substantial weight loss during treatment does not guarantee that the same weight will be maintained after the medication is withdrawn. Continued treatment preserved and extended weight reduction better than withdrawal in the study population.
15. Related Articles and Further Reading
- Vietnam Peptides Knowledge Hub — educational articles on peptide mechanisms, clinical evidence, and research interpretation.
- Peptide FAQ: Research, Storage, and Common Questions — background on peptide research terminology and product considerations.
- Research Products Collection — research-oriented product listings; listings do not establish clinical efficacy or approval.
- Fat Loss Peptide Plan — related educational content about weight-management research themes.
16. Scientific References
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. https://doi.org/10.1001/jama.2023.24945
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392:958–971. https://doi.org/10.1056/NEJMoa2410819
- Authors of the SURMOUNT-4 post hoc analysis. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Network Open. 2025. Full-text article
- Weight regain after cessation of medication for weight management: systematic review and meta-analysis. The BMJ. 2026. Full-text article
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. 2026;93:103796. https://doi.org/10.1016/j.eclinm.2026.103796
- American Diabetes Association. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. 2025. https://doi.org/10.2337/doci25-0008
- US Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. Official US product labeling. Official prescribing information
Conclusion
Tirzepatide research shows that achieving substantial weight loss and maintaining it after treatment ends are separate challenges. SURMOUNT-4 provides direct randomized evidence that participants who continued tirzepatide maintained and extended their weight reduction, whereas those switched to placebo regained a substantial amount of weight over the following year.
Longer-term SURMOUNT-1 data demonstrate sustained benefits during prolonged treatment in participants with obesity and prediabetes, but they do not resolve the question of weight maintenance over several years after discontinuation. Post hoc analyses and systematic reviews suggest that weight regain can be accompanied by deterioration in some cardiometabolic markers, while the long-term consequences for clinical events remain less certain.
The central evidence gap is no longer whether weight regain can occur. It is how best to manage treatment duration, maintenance, interruptions, and discontinuation for different individuals. Researchers need longer follow-up, randomized comparisons of maintenance strategies, broader real-world evidence, and clinically meaningful endpoints.
For readers in Thao Dien and elsewhere, the evidence supports a measured conclusion: tirzepatide can be an effective component of long-term weight management in appropriate clinical settings, but stopping treatment introduces uncertainty about the durability of its benefits. Weight maintenance should be treated as a distinct research and clinical objective, not assumed to follow automatically from successful initial weight loss.